Clinical trials: Platinum Resistant Ovarian Cancer
Ovarian Cancer
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with…
- Trial name
- NCT02580058
- Testing
- avelumab, PLD
- Where
- 295 sites in United States, Australia and 23 more
- Volunteers
- 566 people
- Sponsor
- Pfizer
Ovarian Neoplasms
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This is a phase II open label, non-randomized, study to evaluate the safety and efficacy of Ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant recurrent epithelial ovarian cancer.
- Trial name
- NCT04561817
- Testing
- Ipatasertib, Paclitaxel
- Where
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks.
- Trial name
- NCT06517485
- Testing
- upifitamab rilsodotin
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Mersana Therapeutics
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Ovarian Cancer, Ovarian Carcinoma
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
The ultimate clinical aim of this proposed phase I trial is to evaluate the toxicity and determine the recommended phase II dose of combining the effect of LDFWART following administration of docetaxel for 6 cycles in patients…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovarian Cancer, Recurrent Ovarian Carcinoma
- Trial name
- NCT02083536
- Testing
- Low Dose Fractionated Whole Abdominal Radiation Therapy, Docetaxel
- Sponsor
- University of Miami
Recurrent Platinum Resistant Ovarian Cancer
Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
This study is a Phase I / Dose Expansion open label clinical study in patients with platinum-resistant epithelial ovarian cancer.
- Trial name
- OCTAVE (NCT02028117)
- Testing
- Enadenotucirev
- Where
- 8 sites in Spain, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Akamis Bio
Recurrent Platinum-resistant Ovarian Cancer
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
This study is intend to improve the progression-free survial of the recurrent paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined with apatinib.
- Trial name
- NCT04068974
- Testing
- Camrelizumab (SHR-1210), Apatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
This is a Phase 2 clinical trial, which tests two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF, and durvalumab (MEDI4736)…
- Trial name
- NCT02764333
- Testing
- TPIV200, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00428610
- Testing
- LY573636-sodium
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Recurrent, Platinum-resistant Ovarian Cancer
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
Multicenter Phase II study on Decitabine-Carboplatin combination in platinum resistant ovarian cancer patients. Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances…
- Trial name
- MITO29 (NCT03467178)
- Testing
- Decitabine, Carboplatin, Pegylated Liposomal Doxorubicin
- Where
- Italy
- Volunteers
- 119 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Platinum-resistant Recurrent Ovarian Cancer
Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer
Epithelial ovarian cancer is the most fatal gynecological malignancy. Despite initial therapeutic response, the majority of advanced-stage patients relapse and eventually succumb to chemoresistant disease.
- Trial name
- APPROVE (NCT04348032)
- Testing
- PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd, PLD 40mg/m2 ivgtt q4w
- Where
- 16 sites in China
- Volunteers
- 152 people
- Sponsor
- Chinese Academy of Medical Sciences
Ovarian Cancer Recurrent
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Ovarian cancer is one of the three major malignant tumors of the female reproductive system. Even if newly diagnosed ovarian cancer patients undergo ideal tumor cell reduction surgery and postoperative chemotherapy, 70% to 80% of…
- Trial name
- NCT06660511
- Testing
- Disitamab Vedotin in Combination With Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back…
- Conditions
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- NCT03113487
- Testing
- Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, Ovarian Carcinoma
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
- Trial name
- NCT06964009
- Testing
- DT2216, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Elizabeth Stover, MD, PhD
Ovarian Cancer
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
The primary purpose of this study is to determine the response rate of patients with recurrent platinum resistant ovarian cancer when treated with oral minoxidil.
- Trial name
- NCT05272462
- Testing
- Minoxidil
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Loyola University
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
- Trial name
- NCT03586661
- Testing
- Copanlisib, Niraparib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancers, is a lethal disease with 3,221 new cases reported in 2021 in Korea.
- Conditions
- Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
- Trial name
- NCT07687602
- Volunteers
- 69 people
- Sponsor
- AbbVie
Ovarian Cancer, Endometrial Cancer
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
- Trial name
- NCT07755436
- Testing
- ARR-002
- Where
- 6 sites in United States
- Volunteers
- 180 people
- Sponsor
- ArriVent BioPharma, Inc.
Cytoreductive Surgery
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
This novel study was specifically designed for platinum-resistant recurrent ovarian cancers with PFI<6 months and aimed to compare prognosis of patients who received cytoreductive surgery followed by chemotherapy versus…
- Trial name
- NCT05633199
- Testing
- cytoreductive surgery
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University